COVID-19：武田制药免疫球蛋白试验开始：来自18个国家的500名参与者
武田药神：
-由13家国内外制药公司组成的联盟-
10月9日，该公司宣布已开始“先进的免疫球蛋白制剂”的临床试验。
“高度免疫球蛋白制剂”：
它是通过浓缩和纯化“从新的冠状病毒感染中康复的患者的抗体”而制得的。
来自包括日本在内的18个国家的500人将参加审判。
在临床试验中：
将需要住院的患者随机分为两组
一方面，除了抗病毒药物伦贝西比外，还需一次性注入制剂，
另一组则注入了瑞地昔布和一种没有药性的假药。
研究它是否有效预防加重。
朝日新闻
https://www.asahi.com/articles/ASNB95SF2NB9PLZU001.html
First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine
is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
The CoVIg-19 Plasma Alliance
urges anyone who has recovered from COVID-19 to consider donating plasma.
The CoVIg-19 Plasma Alliance,
an unprecedented collaboration of leading plasma companies supported by global organizations outside the plasma industry,
today confirmed that patients are now being enrolled in the Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) Phase 3 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
The trial will evaluate the safety, tolerability and efficacy of an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalized adults at risk for serious complications of COVID-19 disease.
If successful, the Alliance’s H-Ig may become one of the earliest treatment options for hospitalized COVID-19 patients.